Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een fase 1b/2-studie van BGB-11417 in monotherapie en in verschillende combinaties met dexamethason en carfilzomib bij multipel myeloom

23 oktober 2026 bijgewerkt door: BeOne Medicines

Een fase 1b/2 dosis-escalatie- en cohortuitbreidingsonderzoek om de veiligheid en werkzaamheid van BGB-11417 als monotherapie te bepalen, in combinatie met dexamethason en carfilzomib/dexamethason bij patiënten met recidiverend/refractair multipel myeloom en t(11;14)

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.

Studie Overzicht

Gedetailleerde beschrijving

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Studietype

Ingrijpend

Inschrijving (Geschat)

246

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australië, ACT 2605
        • Werving
        • Canberra Hospital
    • New South Wales
      • Kingswood, New South Wales, Australië, NSW 2747
        • Werving
        • Nepean Hospital
    • Victoria
      • Clayton, Victoria, Australië, VIC 3168
        • Werving
        • Monash Health
      • Fitzroy, Victoria, Australië, VIC 3065
        • Werving
        • St Vincents Hospital Melbourne
      • Melbourne, Victoria, Australië, VIC 3004
        • Werving
        • The Alfred Hospital
    • Western Australia
      • Perth, Western Australia, Australië, WA 6000
        • Werving
        • Royal Perth Hospital
      • Brasília, Brazilië, 70200-730
        • Werving
        • Hospital Sirio Libanes Brasilia
      • Brasília, Brazilië, 70390140
        • Werving
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brazilië, 90110-270
        • Werving
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brazilië, 41253-190
        • Werving
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brazilië, 05652-900
        • Werving
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brazilië, 01401-004
        • Werving
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • São Paulo, Brazilië, 01308-050
        • Werving
        • Hospital Sirio Libanes
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Werving
        • Cross Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Werving
        • British Columbia Cancer Agency the Vancouver Centre
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Werving
        • Princess Margaret Cancer Centre
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100044
        • Werving
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, China, 100000
        • Werving
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, China, 100020
        • Werving
        • Beijing Chao Yang Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400030
        • Werving
        • Chongqing Cancer Hospital
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Voltooid
        • Fujian Medical University Union Hospital
      • Xiamen, Fujian, China, 361003
        • Voltooid
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Werving
        • Sun Yat Sen University Cancer Center
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • Voltooid
        • The Second Hospital of Hebei Medical University
    • Henan
      • Zhengzhou, Henan, China, 450000
        • Werving
        • Henan Cancer Hospital
      • Zhengzhou, Henan, China, 450052
        • Actief, niet wervend
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Werving
        • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, China, 410013
        • Voltooid
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Werving
        • Jiangsu Province Hospital
    • Jiangxi
      • Nanchang, Jiangxi, China, 332000
        • Werving
        • The First Affiliated Hospital of Nanchang University Branch Xianghu
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Werving
        • The First Hospital of China Medical University
    • Shandong
      • Qingdao, Shandong, China, 266000
        • Werving
        • Qingdao Municipal Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Werving
        • Affiliated Zhongshan Hospital of Fudan University
      • Shanghai, Shanghai Municipality, China, 200434
        • Voltooid
        • Shanghai Fourth Peoples Hospital Affiliated to Tongji University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 301617
        • Werving
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
      • Tianjin, Tianjin Municipality, China, 300052
        • Voltooid
        • Tianjin Medical University General Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • Werving
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Aachen, Duitsland, 52074
        • Werving
        • Universitaetsklinikum Aachen
      • Dresden, Duitsland, 01307
        • Werving
        • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
      • Hamburg, Duitsland, 20251
        • Werving
        • Universitatsklinikum Hamburg Eppendorf
      • Würzburg, Duitsland, 97080
        • Werving
        • Universitatsklinikum Wurzburg
      • Poitiers, Frankrijk, 86000
        • Voltooid
        • Chu de Poitiers Site de La Mileterie
      • Alexandroupoli, Griekenland, 68100
        • Werving
        • University Hospital of Alexandroupolis
      • Athens, Griekenland, 115 28
        • Werving
        • General Hospital of Athens Alexandra
      • Ancona, Italië, 60020
        • Werving
        • Azienda Ospedaliera Universitaria Delle Marche
      • Bari, Italië, 70124
        • Werving
        • Azienda Ospedaliera Policlinico Di Bari
      • Bologna, Italië, 40138
        • Werving
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Meldola, Italië, 47014
        • Werving
        • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
      • Milan, Italië, 20141
        • Werving
        • Istituto Europeo Di Oncologia
      • Singapore, Singapore, 119074
        • Werving
        • National University Hospital Singapore
      • Barcelona, Spanje, 08036
        • Actief, niet wervend
        • Hospital Clinic de Barcelona
      • Headington, Verenigd Koninkrijk, OX3 7LE
        • Werving
        • Oxford University Hospitals Nhs Trust Churchill Hospital
      • London, Verenigd Koninkrijk, NW1 2PG
        • Werving
        • University College Hospital
      • Sutton, Verenigd Koninkrijk, SM2 5PT
        • Werving
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35294-0004
        • Werving
        • University of Alabama At Birmingham Hospital
    • California
      • Duarte, California, Verenigde Staten, 91010-3012
        • Werving
        • City of Hope National Medical Center
      • Irvine, California, Verenigde Staten, 92618-2377
        • Werving
        • City of Hope Irvine Lennar
    • Florida
      • Miami, Florida, Verenigde Staten, 33136-2107
        • Werving
        • University of Miami
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322-1013
        • Werving
        • Emory University Winship Cancer Center
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637-1443
        • Werving
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Voltooid
        • Massachusetts General Hospital
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110-1010
        • Werving
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Verenigde Staten, 07601-1915
        • Werving
        • Hackensack University Medical Center
    • New York
      • New York, New York, Verenigde Staten, 10065-6800
        • Werving
        • Memorial Sloan Kettering Cancer Center Mskcc
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210-1240
        • Werving
        • The James Cancer Hospital and Solove Research Institute At Ohio State University
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112-5550
        • Werving
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Verenigde Staten, 98195
        • Werving
        • University of Washington
    • Wisconsin
      • Madison, Wisconsin, Verenigde Staten, 53792-0001
        • Werving
        • University of Wisconsin Carbone Cancer Center
      • Milwaukee, Wisconsin, Verenigde Staten, 53226-3522
        • Werving
        • Medical College of Wisconsin
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Zuid -Korea, 06351
        • Werving
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Zuid -Korea, 06591
        • Werving
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Zuid -Korea, 03722
        • Werving
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
        • Werving
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Zuid -Korea, 05505
        • Werving
        • Asan Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

  2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)

  3. Measurable disease defined as:

    i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio

  4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.

    i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.

    ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.

    1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
    2. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
    3. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
  5. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory

    a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.

  6. Adequate organ function defined as:

    1. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
    2. Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
    3. Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

Exclusion Criteria:

  1. Participant has any of the following conditions:

    1. Non secretory MM (Serum free light chains < 10 mg/dL)
    2. Solitary plasmacytoma
    3. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
    4. Waldenström macroglobulinemia (WM)
    5. Amyloidosis.
    6. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
    7. Chronic respiratory disease that requires continuous oxygen
  2. Significant cardiovascular disease, including but not limited to:

    1. Myocardial infarction ≤ 6 months before screening
    2. Ejection fraction ≤ 50%
    3. Unstable angina≤ 3 months before screening
    4. New York Heart Association Class III or IV congestive heart failure
    5. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    6. Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
    7. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
    8. Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
  3. Known infection with human immunodeficiency virus (HIV)

  4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:

    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
    2. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

Administered orally daily

Andere namen:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Administered subcutaneously weekly

Administered orally daily

Experimenteel: Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

Administered orally daily

Andere namen:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Deel 1 en 2: Aantal deelnemers dat een of meer behandelings-opkomende bijwerkingen (Teaes), ernstige bijwerkingen (SAE's) meldt, bijwerkingen die leiden tot stopzetting en bijwerkingen van speciaal belang (aesis).
Tijdsspanne: Tot 30 dagen na de laatste dosis studiamendheid
Tot 30 dagen na de laatste dosis studiamendheid
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Tijdsspanne: Up to 28 days

DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.

Up to 28 days
Part 2: Overall response rate (ORR) as Assessed by Investigator
Tijdsspanne: Approximately 4 years

Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria

Approximately 4 years
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Tijdsspanne: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR)

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Tijdsspanne: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

defined as the percentage of participants with a documented CR or sCR

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Deel 1: Gebied onder de plasmaconcentratie-tijdcurve tijd 0 tot de laatste meetbare concentratie (AUCLAST) na een enkele dosis sonrotoclax
Tijdsspanne: Cyclus 1 (elke cyclus is maximaal 28 dagen)
Cyclus 1 (elke cyclus is maximaal 28 dagen)
Deel 1: Maximaal waargenomen plasmaconcentratie (Cmax) na een enkele dosis Sonrotoclax
Tijdsspanne: Cyclus 1 (elke cyclus is maximaal 28 dagen)
Cyclus 1 (elke cyclus is maximaal 28 dagen)
Deel 1: Tijd om Cmax (TMAX) te bereiken na een enkele dosis Sonrotoclax
Tijdsspanne: Cyclus 1 (elke cyclus is maximaal 28 dagen)
Cyclus 1 (elke cyclus is maximaal 28 dagen)
Deel 1: bij Steady-State: AUC Last, SS
Tijdsspanne: Cyclus 2 (elke cyclus is maximaal 28 dagen)
Cyclus 2 (elke cyclus is maximaal 28 dagen)
Deel 1: bij Steady-State: Cmax, SS
Tijdsspanne: Cyclus 2 (elke cyclus is maximaal 28 dagen)
Cyclus 2 (elke cyclus is maximaal 28 dagen)
Deel 1: bij Steady-State: Trough Plasma Concentration (Ctrough) SS
Tijdsspanne: Cyclus 2 (elke cyclus is maximaal 28 dagen)
Cyclus 2 (elke cyclus is maximaal 28 dagen)
Deel 1: bij steady-state: tijd om Cmax te bereiken (Tmax, SS)
Tijdsspanne: Cyclus 2 (elke cyclus is maximaal 28 dagen)
Cyclus 2 (elke cyclus is maximaal 28 dagen)
Part 2: Time to response (TTR) as Assessed by Investigator
Tijdsspanne: Approximately 4 years

TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better

Approximately 4 years
Part 2: Duration of response (DOR) as Assessed by Investigator
Tijdsspanne: Approximately 4 years

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method.

Approximately 4 years
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Tijdsspanne: Approximately 4 years

PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first

Approximately 4 years
Part 2: Overall survival (OS) as Assessed by Investigator
Tijdsspanne: Approximately 4 years

OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause

Approximately 4 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

16 september 2021

Primaire voltooiing (Geschat)

1 november 2026

Studie voltooiing (Geschat)

1 november 2026

Studieregistratiedata

Eerst ingediend

7 juli 2021

Eerst ingediend dat voldeed aan de QC-criteria

20 juli 2021

Eerst geplaatst (Werkelijk)

22 juli 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

23 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD-tijdsbestek voor delen

See plan description

IPD-toegangscriteria voor delen

See plan description

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren